The first event of its kind, this 4-hour virtual summit focuses specifically on how innovators can use Regulation A+ to raise capital in healthcare and life sciences, including medtech, biotech, and pharmaceuticals.
Whether you’re developing a revolutionary app or launching a groundbreaking product, having the right funding strategy is essential to fuel your growth and turn your ideas into reality. In this blog post, we will explore the various fundraising options available to startups and provide guidance on how to choose the one that best aligns with your business goals and objectives.
Broker-dealers are an important element of the fundraising process, and selecting the right one is crucial to your success. Some states require issuers to work with a broker-dealer.
The LSI Blog features an interview with Scott Huennekens, the keynote speaker at the 2021 Emerging Medtech Summit, discussing his career, his “Go, go, go” philosophy.
RegTech are the various technology solutions to improve compliance through efficiency, allowing companies to keep up with evolving regulations.
We take for granted that we can easily trade stocks online, move them between brokers, and automatically receive dividends and shareholder communications. The recent rapid growth of private placements has pushed the need for similar infrastructure in the private markets.
The LSI Emerging Medtech Summit 2021 kicks off tomorrow. Over 180 medtech companies are presenting, with some 300 investors and strategics attending.
Valuations are at record highs, thanks to strong IPO exits, broader economic recovery, and growing participation by nontraditional investors. Don’t sell yourself short—your company may well be worth far more than your balance sheet would indicate.
Regulation A+ may finally be starting to get the media exposure it deserves. This story includes Cityzenith ‘s Reg A+ raise mentioned side-by-side with celebrity-backed venture funds.
Health Diagnostic Startups Raised Record $4.8B In 2020
Are diagnostic companies harder to get funded than therapeutics? Harder or not, there’s no shortage of funding for diagnostics, even post-pandemic.